Astellas Signs License For Regeneron’s VelocImmune To Bolster Antibody Platform
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal, valued at potentially $120 million, is Regeneron’s second for the human monoclonal antibody discovery technology.